关于金宇生物技术股份有限公司 非经营性资金占用及其他关联 资金往来的专项说明 型机械发)出名属信击分 场 5 层 邮编 1000 86 10 8566 5588 86 10 8566 5120 arantthornton.cr 关于金宇生物技术股份有限公司 非经营性资金占用及其他关联资金往来的专项说明 致同专字(2025)第 441A009988 号 金宇生物技术股份有限公司全体股东: 我们接受金宇生物技术股份有限公司(以下简称"生物股份公司")委 托,根据中国注册会计师执业准则审计了生物股份公司 2024年 12月 31日的合 并及公司资产负债表,2024年度合并及公司利润表、合并及公司现金流量表、 合并及公司股东权益变动表和财务报表附注,并出具了致同审字(2025)第 441A016663 号无保留意见审计报告。 根据《上市公司监管指引第8号——上市公司资金往来、对外担保的监管 要求》等有关规定,生物股份公司编制了本专项说明所附的金宇生物技术股 份有限公司 2024 年度非经营性资金占用及其他关联资金往来情况汇总表（以 下简称"汇总表"）。 致同会计师事务所（特殊普通合伙） 目 录 关于金字生物技术股份有 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 351,572,845.58, representing a year-on-year increase of 1.06% compared to CNY 347,901,401.91 in the same period last year[4] - Net profit attributable to shareholders decreased by 27.57% to CNY 76,481,084.90 from CNY 105,586,820.64 in the previous year[4] - The net profit after deducting non-recurring gains and losses fell by 38.09% to CNY 59,015,598.31, down from CNY 95,324,670.79[4] - Basic earnings per share were CNY 0.07, a decrease of 30.00% from CNY 0.10 in the previous year[5] - The weighted average return on net assets was 1.44%, down from 1.95% in the previous year, a decrease of 0.51 percentage points[5] - The total comprehensive income increased to ¥118,882,968.21 from ¥109,828,615.86, marking an increase of about 8.5% year-over-year[19] Cash Flow and Assets - The net cash flow from operating activities decreased by 42.62% to CNY 26,218,397.99, compared to CNY 45,691,311.67 in the same period last year[4] - Current assets as of March 31, 2025, totaled RMB 2,098,516,975.45, down from RMB 2,191,397,901.49 as of December 31, 2024, indicating a decrease of about 4.23%[14] - Cash and cash equivalents decreased to RMB 1,009,736,405.59 from RMB 1,139,534,619.01, representing a decline of approximately 11.39%[14] - Total assets at the end of the reporting period were CNY 6,698,922,549.94, a decrease of 0.97% from CNY 6,764,669,055.34 at the end of the previous year[5] - Total liabilities decreased to RMB 1,291,702,099.76 from RMB 1,349,290,645.97, a reduction of approximately 4.26%[16] - The cash and cash equivalents at the end of the period decreased to ¥697,642,390.75 from ¥1,135,949,930.04, a drop of approximately 38.6%[23] Shareholder Equity and Non-Recurring Items - Shareholders' equity attributable to shareholders decreased by 0.20% to CNY 5,303,456,826.89 from CNY 5,314,336,328.75 at the end of the previous year[5] - The company reported non-recurring gains and losses totaling CNY 17,465,486.59 for the period[7] - The company reported other comprehensive income after tax of ¥41,680,353.86, significantly higher than ¥3,297,272.18 from the previous period[19] Operational Costs and Expenses - The total operating costs increased to ¥283,520,948.56 from ¥230,815,022.46, representing a growth of approximately 22.8% year-over-year[18] - The company's management reported an increase in research and development expenses to ¥39,703,032.62 from ¥31,490,190.73, an increase of about 26.1% year-over-year[18] Market Conditions and Strategic Insights - The decline in net profit and cash flow was primarily attributed to intensified industry competition and adjustments in marketing strategies[7] - There were no significant new strategies or product developments mentioned during the earnings call[12]

Financial Performance - The company's operating revenue for 2024 was CNY 1,255,455,757.88, a decrease of 21.45% compared to CNY 1,598,225,460.25 in 2023[22]. - The net profit attributable to shareholders for 2024 was CNY 108,985,186.46, down 61.57% from CNY 283,630,790.16 in 2023[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 49,487,344.61, a decline of 80.55% compared to CNY 254,459,867.96 in 2023[22]. - The net cash flow from operating activities for 2024 was CNY 289,552,214.10, a decrease of 30.20% from CNY 414,833,263.67 in 2023[22]. - The total assets at the end of 2024 were CNY 6,764,669,055.34, down 1.57% from CNY 6,872,581,837.59 at the end of 2023[22]. - Basic earnings per share fell by 61.54% to CNY 0.10, and the diluted earnings per share were not disclosed[24]. - The weighted average return on equity decreased to 1.95%, down 3.48 percentage points from the previous year[24]. - The company reported a significant decline in sales volume for several key products, including a 40.74% drop in sales of live pig fever vaccine[58]. Research and Development - The company maintained a high level of R&D investment, with CNY 179 million allocated to original product development, accounting for 14.25% of total revenue[33]. - The company has established multiple R&D platforms, including a national engineering laboratory for veterinary vaccines, enhancing research efficiency and innovation capabilities[44]. - The company is focusing on innovative vaccine technologies, including mRNA vaccines, to address critical challenges in the aquaculture sector[33]. - The company has developed a unique combination of vaccines for brucellosis, significantly reducing the incidence of the disease in livestock and humans[35]. - The company has received national recognition for its intelligent manufacturing and digital transformation initiatives, including being designated as an AI production demonstration base[35]. - The company is exploring advanced technologies such as mRNA vaccines and multi-valent vaccines to address critical animal diseases[47]. Market and Industry Trends - The domestic animal health market has grown from RMB 41.213 billion in 2013 to RMB 69.651 billion in 2023, with the veterinary biological products market increasing from RMB 9.4 billion to RMB 16.276 billion[36]. - The average price of live pigs in 2024 is approximately RMB 17.08 per kilogram, reflecting a year-on-year increase of 10.9%[37]. - The national scale of pig farming is expected to exceed 70% by 2024, indicating a trend towards increased concentration and specialization in the industry[37]. - The animal health industry is experiencing steady growth, with a compound annual growth rate (CAGR) of 6.45% in output value and 6.16% in sales over the past decade, despite some downturns in 2018 and 2022[98]. Corporate Governance - The company conducted 2 shareholder meetings during the reporting period, ensuring equal rights for all shareholders, particularly minority shareholders[109]. - The board of directors held 6 meetings, enhancing decision-making capabilities through training on relevant laws and regulations[109]. - The supervisory board convened 5 times, ensuring compliance with financial and operational regulations to protect shareholder interests[110]. - The company emphasizes information disclosure and investor relations, ensuring equal access to information for all shareholders[110]. - The company has established a commitment to maintain operational independence from its controlling shareholders[175]. Environmental Responsibility - The company has invested CNY 1,384.04 million in environmental protection during the reporting period[150]. - The company has implemented an annual self-monitoring plan for wastewater, waste gas, and noise, with online automatic monitoring for key pollutants[161]. - The company has developed a steam waste heat recovery project to enhance energy efficiency and reduce carbon emissions[168]. - The company has established a water reuse pool for irrigation and cleaning purposes, promoting resource conservation[169]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[164]. Employee Engagement and Compensation - The total number of employees in the parent company and major subsidiaries is 1,740, with 1,714 in subsidiaries and 26 in the parent company[131]. - The company has a strategic focus on expanding its employee stock ownership plan to enhance employee engagement and retention[115]. - The total compensation for the chairman during the reporting period was 130.27 million yuan, while the vice chairman and president received 118.84 million yuan[115]. - The company emphasizes a "get and share" philosophy in its compensation policy, encouraging performance-driven rewards to enhance market competitiveness[132]. Financial Management - The company has recognized an impairment provision of CNY 2,595,022.42 for the investment product due to the inability to redeem on time, influenced by various internal and external factors in the real estate industry[191]. - The company has invested CNY 45,773,885.46 in broker financial products, with an outstanding balance of CNY 43,330,560.93[189]. - The company has committed to maintaining financial independence and a complete labor management system, ensuring no overlap with controlled entities[174]. - The company will ensure compliance with relevant laws and regulations regarding shareholding and stock issuance[178].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 金宇生物技术股份有限公司（以下简称"公司"）分别于 2023 年 2 月 7 日、 2023 年 3 月 16 日、2023 年 5 月 9 日、2023 年 5 月 31 日，召开第十一届董事会第 五次会议、2023 年第二次临时股东大会、第十一届董事会第九次会议、2022 年年 度股东大会，审议通过《关于公司符合向特定对象发行 A 股股票条件的议案》等 公司向特定对象发行 A 股股票（以下简称"本次发行"）的相关议案，并于 2024 年 1 月 12 日召开第十一届董事会第十二次会议，对本次发行方案进行部分调整， 于 2024 年 3 月 15 日召开 2024 年第一次临时股东大会，审议通过延长本次发行相 关决议和相关授权的有效期的议案。根据前述决议，公司本次发行相关决议和相关 授权的有效期为自公司股东大会审议通过本次发行议案之日起十二个月，即有效期 至 2025 年 3 月 15 日。 鉴于公司本次发行相关决议和相关授权的有效期已届满，而公司本次发行相关 事项尚在进行中， ...

证券代码：600201 证券简称：生物股份 公告编号：临 2025-013 本议案尚需提交公司股东大会审议。 二、审议并通过《公司 2024 年年度报告及摘要》 与会董事一致认为，公司 2024 年年度报告真实地反映了公司 2024 年度的财 务状况和经营成果。本议案已经公司董事会审计委员会审议通过。 表决结果：8 票同意、0 票反对、0 票弃权。 本议案尚需提交公司股东大会审议。 具体内容详见公司披露在上海证券交易所网站（www.sse.com.cn）上的《金 宇生物技术股份有限公司 2024 年年度报告》全文及摘要。 金宇生物技术股份有限公司 第十一届董事会第十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 金宇生物技术股份有限公司(以下简称"公司")第十一届董事会第十八次会 议通知于 2024 年 4 月 7 日以电子邮件、书面形式发出，会议于 2024 年 4 月 23 日下午 14：00 在公司会议室以现场和通讯表决相结合的方式召开, 应出席董事 8 人，实际出席董事 8 人。公司监事、高级管理人员 ...

Investment Rating - The report maintains a "Recommended" investment rating for the industry, suggesting a potential upside of over 15% relative to benchmark indices [4]. Core Insights - The swine industry shows stable breeding profits, with a focus on capacity reduction logic. The average price of external three yuan pigs was 15.0 CNY/kg, up 2.1% week-on-week, while the average weight of pigs sold was 128.6 kg, down 0.2% [19][20]. - The beef industry is at an inflection point, with strong price performance continuing. The average price of calves was 28.2 CNY/kg, up 2.1%, and the average price of fattened cattle was 25.8 CNY/kg, up 0.7% [23][30]. - The white chicken market is affected by ongoing avian influenza, with significant impacts on breeding stock and prices. The average price of white feather broiler chicks was 2.8 CNY/chick, up 9.5% [31][34]. - The animal health sector is seeing a recovery in demand as breeding supply stabilizes, with a notable increase in the issuance of vaccines [48][49]. Summary by Sections Swine Industry - The average price of external three yuan pigs was 15.0 CNY/kg, reflecting a week-on-week increase of 2.1%. The average weight of pigs sold was 128.6 kg, down 0.2%. The price of 15 kg external three yuan piglets was 668 CNY/head, with a slight decrease of 0.05% [19][21]. - Supply pressure remains stable, with normal sales rhythms from large producers and limited sales from smallholders. The demand side shows increased activity from secondary breeding, but overall consumption remains weak [20][21]. - The report recommends companies such as Muyuan Foods, Wens Foodstuff Group, and New Hope Liuhe for investment [20]. Beef Industry - The beef breeding industry is entering a capacity release phase, with the earliest signs of a price bottom forming. The report anticipates a potential recovery in the industry by late 2025 or early 2026 [23][30]. - The average wholesale price of beef was 61.4 CNY/kg, reflecting a slight increase of 0.2% [29][30]. - Recommended companies include Fucheng Co. and Guangming Meat Industry, focusing on integrated breeding and sales [23]. Poultry Industry - The average price of white feather broiler eggs was 1.6 CNY/egg, up 2.0%, while the average price of white feather broilers was 3.7 CNY/kg, up 2.2% [31][34]. - The report highlights the impact of avian influenza on breeding imports, particularly from the U.S. and New Zealand, which has been suspended for over three months [31][32]. - Recommended companies include Yisheng Livestock and He Feng Food [31]. Animal Health Sector - The demand for animal health products is expected to recover as breeding supply stabilizes. The issuance of vaccines has shown significant increases, particularly for swine diseases [48][49]. - The report recommends companies like Kexin Biological and Zhongmu Biotechnology, which are positioned to benefit from the recovery in the animal health market [49].

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●会议召开时间：2025年4月30日（星期三）16:00-17:00 ●会议召开地点：上海证券交易所上证路演中心 （一）会议召开时间：2025年4月30日（星期三）16:00-17:00 （二）会议召开地点：上证路演中心 （三）会议召开方式：上证路演中心网络互动 三、 参加人员 （网址：http://roadshow.sseinfo.com） ●会议召开方式：上证路演中心网络互动 ●投资者可于2025年4月23日（星期三）至4月29日（星期二）16:00前登录上证路演中心网站首页点 击"提问预征集"栏目或通过公司投资者关系邮箱（ir@cansinotech.com）进行提问。公司将在说明会上 对投资者普遍关注的问题进行回答。 康希诺生物股份公司（以下简称"公司"）已于2025年3月26日发布2024年年度报告，并将于2025年4月30 日发布2025年第一季度报告。为便于广大投资者更全面深入地了解公司经营成果 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 股票简称：保龄宝 股票代码：002286 公告编号：2025-014 董事会 2025年4月20日 证券代码：002286 证券简称：保龄宝 公告编号：2025-015 关于解聘公司副总经理的公告 公司董事会及全体成员保证公告内容的真实、准确和完整，不存在虚假记录、误导性陈述或者重大遗 漏。 保龄宝生物股份有限公司（以下简称"公司"）于2025年4月20日召开第六届董事会年第八次会议，审议 通过《关于解聘公司副总经理的议案》。 依据《公司法》《公司章程》中有关规定，经总经理提名，董事会提名委员会审核，公司董事会同意解 聘张国刚先生副总经理职务，解聘后不在公司担任任何职务，解聘自本次董事会审议通过之日起生效。 截至本公告披露日，张国刚先生持有公司股份90,600股。张国刚先生将继续遵守《上市公司股东减持股 份管理暂行办法》《深圳证券交易所上市公司自律监管指引第1号一一主板上市公司规范运作》《深圳 证券交易所上市公司自律监管指引第18号一一股东及董事、高级管理人员减持股份》等相关法律法规的 规定。 特此公告。 保龄宝生物股份有限公司 保龄宝生物股份有限公司 保龄宝 ...

证券代码：688739 证券简称：成大生物 公告编号：2025-020 辽宁成大生物股份有限公司 关于首次公开发行限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 辽宁成大生物股份有限公司（以下简称"成大生物"或"公司"或"发行人"）本次上市流通的限售股为公 司控股股东辽宁成大股份有限公司（以下简称"辽宁成大"）所持股份，本次股票上市类型为首发限售股 份。股票认购方式为网下，上市股数为227,663,764股，约占公司总股本的54.67%。 ● 辽宁成大作为公司的控股股东，将严格遵守《辽宁成大生物股份有限公司首次公开发行股票并在科创 板上市招股说明书》中关于股份减持的相关承诺，并严格执行《上市公司股东减持股份管理暂行办法》 第十一条"最近二十个交易日中，任一日股票收盘价（向后复权）低于首次公开发行时的股票发行价格 的，上市公司首次公开发行时的控股股东、实际控制人及其一致行动人不得通过证券交易所集中竞价交 易或者大宗交易方式减持股份"之规定。 ● 本次股票上市流通总数为227,663,7 ...

Investment Rating - The report maintains a "Recommended" rating for the agriculture, forestry, animal husbandry, and fishery industry [1] Core Views - The report highlights the weak fluctuation of pig prices, with expectations of a downward trend in the short term and a long-term weak operation in 2025 due to increased supply and weak demand [4][14] - The poultry sector may see price improvements due to the impact of tariffs and a shortage of quality breeding stock caused by avian influenza [5][28] - The animal health sector is expected to benefit from improved downstream demand and external expansion opportunities, with rising prices for key products like Tylosin [6][41] - The planting sector is experiencing price fluctuations for major grains, with a focus on the commercialization of genetically modified seeds [8][46] - The feed sector is seeing a decline in prices, with recommendations for companies like Haida Group [8][49] - The pet market continues to grow rapidly, with strong performance from domestic brands and recommendations for companies in the pet food and medical sectors [8][54][57] Summary by Sections Pig Industry - Pig prices are expected to adjust slightly, with a forecast of weak performance in 2025 due to increased supply [4][14] - As of April 10, 2025, the average price of live pigs is 14.6 CNY/kg, with no change from the previous week [14] Poultry Industry - The poultry sector may see price increases due to tariff impacts and a lack of quality breeding stock [5][28] - The average price of broiler chickens is 3.75 CNY/lb, reflecting a weekly increase [28] Animal Health - The animal health sector is experiencing improved profitability, with Tylosin prices rising significantly [6][41] - The report suggests focusing on companies with expected external expansion, such as Reap Bio [6] Planting Sector - Major grain prices are fluctuating, with corn priced at 2199 CNY/ton and wheat at 2422 CNY/ton [8][46] - The report recommends companies involved in genetically modified seed development [8] Feed Sector - Feed prices are declining, with pig feed at 3.35 CNY/kg [8][49] - The report suggests focusing on companies like Haida Group due to expected industry consolidation [8] Pet Industry - The pet market is projected to reach 300.2 billion CNY in 2024, with a growth rate of 7.5% [8][54] - Recommendations include companies like Guobao Pet and Zhongchong Co., which are experiencing significant growth [8][57]